Gene Biotherapeutics, Inc. Proceeds from Notes Payable
Gene Biotherapeutics, Inc. reported Proceeds from Notes Payable of $193.48 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2022-04-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-04-14
- Gene Biotherapeutics, Inc. proceeds from notes payable for the quarter ending 2020-12-31 was $12.32K, a 21.63% increase year-over-year.
- Gene Biotherapeutics, Inc. proceeds from notes payable for the quarter ending 2020-09-30 was $12.32K, a 90.42% decline year-over-year.
- Gene Biotherapeutics, Inc. proceeds from notes payable for the quarter ending 2020-06-30 was $37.07K, a 350.63% increase year-over-year.
- Gene Biotherapeutics, Inc. proceeds from notes payable for the quarter ending 2020-03-31 was $131.76K, a 1519.25% increase year-over-year.
- Gene Biotherapeutics, Inc. proceeds from notes payable for fiscal 2020 was $193.48K, a 24.66% increase from fiscal 2019.
- Gene Biotherapeutics, Inc. proceeds from notes payable for fiscal 2019 was $155.21K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2020-12-31 | $12.32K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-04-14 | $24.65K derived: sum of 2 quarters · filed 2022-04-14 | $61.72K derived: sum of 3 quarters · filed 2022-04-14 | $193.48K 10-K/A · filed 2022-04-14 |
| 2020-09-30 | $12.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $49.40K derived: sum of 2 quarters · filed 2021-10-27 | $181.16K 10-Q · filed 2021-10-27 | $191.29K derived: sum of 4 quarters · filed 2022-04-14 |
| 2020-06-30 | $37.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-09-17 | $168.83K 10-Q · filed 2021-09-17 | $178.96K derived: sum of 3 quarters · filed 2022-04-14 | $307.68K derived: sum of 4 quarters · filed 2022-04-14 |
| 2020-03-31 | $131.76K 10-Q · filed 2021-09-03 | $141.89K derived: sum of 2 quarters · filed 2022-04-14 | $270.60K derived: sum of 3 quarters · filed 2022-04-14 | $278.83K derived: sum of 4 quarters · filed 2022-04-14 |
| 2019-12-31 | $10.13K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-04-14 | $138.84K derived: sum of 2 quarters · filed 2022-04-14 | $147.07K derived: sum of 3 quarters · filed 2022-04-14 | $155.21K 10-K/A · filed 2022-04-14 |
| 2019-09-30 | $128.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $136.94K derived: sum of 2 quarters · filed 2021-10-27 | $145.08K 10-Q · filed 2021-10-27 | |
| 2019-06-30 | $8.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-09-17 | $16.36K 10-Q · filed 2021-09-17 | ||
| 2019-03-31 | $8.14K 10-Q · filed 2021-09-03 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-03-21 | $30.00K 10-Q · filed 2017-03-21 | ||
| 2016-06-30 | $30.00K 10-Q · filed 2017-03-06 |